Article Details
Retrieved on: 2025-03-28 02:38:03
Tags for this article:
Click the tags to see associated articles and topics
Summary
The article discusses FDA approvals of Fresenius Kabi Biopharma's denosumab biosimilars, expanding biopharma options for treating osteoporosis, bone metastasis, and multiple myeloma. It mentions Amgen, the reference products' developer, and the impact of biosimilars.
Article found on: www.centerforbiosimilars.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here